Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III.

Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Barbato E, Garcia-Garcia HM, Waksman R; BIOSOLVE-II and III investigators.

Catheter Cardiovasc Interv. 2018 Aug 5. doi: 10.1002/ccd.27680. [Epub ahead of print]

PMID:
30079472
2.

Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III.

Haude M, Ince H, Kische S, Abizaid A, Tölg R, Alves Lemos P, Van Mieghem NM, Verheye S, von Birgelen C, Christiansen EH, Wijns W, Garcia-Garcia HM, Waksman R.

EuroIntervention. 2017 Jul 20;13(4):432-439. doi: 10.4244/EIJ-D-17-00254.

Supplemental Content

Loading ...
Support Center